In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q1 job market performance and what it signals for the coming months.

Original title: “Bonus: Q1 2026 Job Market Update”

With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.

Original title: “With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026”

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.

Original title: “Lilly investing billions to prepare for overseas oral GLP-1 launches”

Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.

Original title: “Lilly wants to bridge cancer care gap with $300M ADC biotech buy”

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise.

Original title: “Novo teams with OpenAI; Ideaya gets muted response to eye drug data”

The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Septune, Inc., located in San Juan, Puerto Rico, to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.

Original title: “Prospective Grant of Exclusive Patent License: Catheter-Based Myotomy Devices And Systems”

Two health-care companies began formally marketing US initial public offerings raising as much as $693 million in aggregate, as listing activity in the once-prolific sector increases. Obesity biotech Kailera Therapeutics Inc. revealed it is seeking to raise as much as $533 million from an IPO to help fund the development of its pipeline of obesity drugs.

Original title: “Life Science Firms Seek $693 Million in US IPOs as Pace Picks Up - Bloomberg”

The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.

Original title: “AbbVie enters world of pain in up to $715M deal with China’s Haisco”

Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company's cancer portfolio, according to Truist Securities.

Original title: “Regeneron enters radiopharma ring with up to $4.3B Telix alliance”

Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.

Original title: “Second rejection for tumor destroyer puts Replimune on a ‘challenging path’”

By Tristan Manalac - BIoSpace - The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence. After hitting a historic low in 2025—only eight biotechs went public, as per a BioSpace tally, the lowest in ... By Tristan Manalac - BIoSpace - The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence. After hitting a historic low in 2025—only eight biotechs went public, as per a BioSpace tally, the lowest in the post-pandemic era—initial The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence. After hitting a historic low in 2025—only eight biotechs went public, as per a BioSpace tally, the lowest in the post-pandemic era—initial public offerings (IPOs) seem to be on the upswing this year.

Original title: “Biotech IPOs Rebound as AI Takes a More Central Role in Drug Development - World Stem Cell Summit”

Connected medical devices are transforming healthcare and clinical trials, driving advances in patient care and next-gen therapies shaping the future.

Original title: “Connected medical devices: Smarter care starts here”

A smarter approach to dermatology trials—built for durability and real-world impact.

Original title: “Rethinking dermatology trial design for late-stage success”